Clinical trials: Coronary Arteriosclerosis
Coronary Artery Disease
A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.
The primary objective of the study is to assess the diagnostic efficacy (specificity and sensitivity) of flurpiridaz F18 injection PET myocardial perfusion imaging (MPI) compared to single photon emission computed tomography…
- Trial name
- NCT01347710
- Testing
- Flurpiridaz F18, 99mTechnicium (sestamibi or tetrofosmin)
- Where
- 81 sites in United States, Canada and 2 more
- Volunteers
- 795 people
- Sponsor
- Lantheus Medical Imaging
Coronary Artery Disease (CAD), Peripheral Arterial Disease
A Study of SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial Disease
The study is a Phase 2a, randomized, double-blind, placebo-controlled, sequential cohort study to evaluate the pharmacodynamics (PD), safety and pharmacokinetics (PK) of multiple doses of SRSD107 in participants with coronary…
- Trial name
- NCT07318155
- Testing
- SRSD107, 0.9 % sodium chloride
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Sirius Therapeutics Co., Ltd.
Coronary Heart Disease (CHD)
A Biorepository for Coronary Heart Disease in Qatar
Coronary heart disease (CHD) poses a major health burden in the Gulf countries. It is the leading cause of mortality and morbidity in the world and poses an enormous societal burden in the Gulf countries.
- Trial name
- QCBio (NCT03427489)
- Where
- Qatar
- Volunteers
- 2,100 people
- Sponsor
- Hamad Medical Corporation
Coronary Artery Disease
Cruz HBR Registry - Post-market Registry to Evaluate the Safety and Efficacy of the Supraflex Cruz Stent
This is a prospective, multicenter, open-label, single-arm registry. The primary objective of this registry is to confirm the results of the Supraflex Cruz stent in real life all-comer patients (800 patients as in the Supraflex…
- Trial name
- NCT04138238
- Testing
- Supraflex Cruz Sirolimus-eluting Stent
- Where
- 26 sites in France, Germany and 1 more
- Volunteers
- 1,200 people
- Sponsor
- Sahajanand Medical Technologies Limited
Coronary Artery Disease
A Prospective, Single-site, Single-group Value Study on the Diagnosis of Functional Myocardial Ischemia Based on IVUS Plaque Characteristics
This study aims to evaluate the accuracy of IVUS-calculated percent atheroma volume (PAV) for diagnosing functional myocardial ischemia, using FFR as the gold standard.
- Trial name
- NCT07176585
- Where
- China
- Volunteers
- 105 people
- Sponsor
- Insight Lifetech Co., Ltd.
Hypertension, Angina Pectoris
Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
In this survey, to collect the safety and efficacy information of Amlodipine /Atorvastatin (Caduet® Combination Tablets) in daily medical practice will be examined.
- Conditions
- Hypertension, Angina Pectoris, Hypercholesterolemia, Familial Hypercholesterolemia
- Trial name
- NCT01107743
- Testing
- Amlodipine/Atorvastatin
- Volunteers
- 1,291 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))
The REVEALPLAQUE Study: A pRospEctiVe, multicEnter Study to AnaLyze PLAQUE Using CCTA
This study will evaluate the level of agreement between noninvasive CCTA (coronary computed tomography angiography)-based quantification and characterization of coronary atherosclerosis and invasive IVUS (intravascular…
- Trial name
- REVEALPLAQUE (NCT05138289)
- Testing
- Total Plaque Volume
- Where
- United States
- Volunteers
- 258 people
- Sponsor
- HeartFlow, Inc.
Coronary Disease
CoStar™ Paclitaxel-Eluting Coronary Stent Catheter System Evaluation
This study is designed to evaluate the performance and safety of a new catheter system.
- Trial name
- NCT00422435
- Testing
- CoStar™ Paclitaxel-Eluting Coronary Stent with SRX catheter
- Where
- Belgium
- Volunteers
- 107 people
- Sponsor
- Conor Medsystems
ST-segment Elevation Myocardial Infarction (STEMI), Cardiogenic Shock
The RECOVER IV Trial
The purpose of this study is to assess whether hemodynamic support with an Impella-based treatment strategy initiated prior to percutaneous coronary intervention (PCI) in patients with ST-Segment Elevation Myocardial Infarction…
- Trial name
- RECOVER IV (NCT05506449)
- Testing
- Impella CP®, Standard of Care
- Where
- 7 sites in United States, Denmark and 2 more
- Volunteers
- 4 people
- Sponsor
- Abiomed Inc.
Coronary Artery Disease
The Study to Evaluate Patient Outcome Using Distal Protection Combined With the BX Velocity.
The primary objective is to evaluate the use of the AngioGuard™ device combined with the Bx Velocity™ on patient outcome at one month.
- Trial name
- DISCOVER (NCT00264043)
- Testing
- emboli capturing guidewire device combined with stent
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Cordis US Corp.
Coronary Artery Disease
Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart
CT (computed tomography) angiography (CTA) is an examination similar to a CAT scan that uses x-rays and a contrast medium (also called dye) to visualize blood flow in arteries and veins throughout the body VISIPAQUE™ will be…
- Trial name
- NCT00348608
- Testing
- iodixanol
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- GE Healthcare
Coronary Artery Disease, Myocardial Infarction
Disrupt CAD III With the Shockwave Coronary IVL System
The study design is a prospective, multicenter, single-arm, global IDE study to evaluate the safety and effectiveness of the Shockwave Medical Coronary Intravascular Lithotripsy (IVL) System in de novo, calcified, stenotic…
- Trial name
- NCT03595176
- Testing
- Lithotripsy
- Where
- 48 sites in United States, France and 2 more
- Volunteers
- 431 people
- Sponsor
- Shockwave Medical, Inc.
Stable Coronary Artery Disease
RBD1119 in Coronary Artery Disease (CAD)
CAD is driven by atherosclerosis in the coronary arteries and is a major cause of myocardial infarction, heart failure, arrhythmias, and premature death.
- Trial name
- NCT07884136
- Testing
- RBD1119
- Where
- 16 sites in Poland, Sweden
- Volunteers
- 200 people
- Sponsor
- Ribocure Pharmaceuticals AB
Coronary Artery Disease, Myocardial Ischaemia
SeQuent® SCB "All Comers" Post Market Clinical Follow-up (PMCF)
The aim of the study is to assess continued safety and efficacy of the SeQuent® SCB. The product under investigation will be used in routine clinical practice according to the latest European Society of Cardiology (ESC)…
- Trial name
- SCORE (NCT04470934)
- Testing
- SeQuent® SCB drug-coated balloon catheter
- Where
- Germany
- Volunteers
- 1,302 people
- Sponsor
- B. Braun Melsungen AG
Myocardial Infarction, Angina
An Observational Study of Cholesterol in Coronary Arteries
In April 2008, a coronary catheter based imaging system, LipiScan, was cleared by the FDA for use in detecting lipid core containing containing plaques of interest (LCP). These plaques are rich in cholesterol.
- Conditions
- Myocardial Infarction, Angina, Coronary Artery Disease, Myocardial Ischemia
- Trial name
- COLOR (NCT00831116)
- Testing
- Intravascular Near Infrared Spectroscopy
- Where
- 22 sites in United States
- Volunteers
- 2,067 people
- Sponsor
- Infraredx
Coronary Disease, Drug Eluting Stent
Comparison One vs Six Months of Dual Antiplatelet Therapy After Implanted Firehawk TM Stent in High Bleeding Risk Patients With Coronary Artery Disease
This study is to assess the clinical non-inferiority of 1 month (short-term) vs 6 months (long-term) of dual anti-platelet therapy in patients undergoing percutaneous intervention implanted sirolimus -eluting stent with abluminal…
- Conditions
- Coronary Disease, Drug Eluting Stent, Percutaneous Coronary Intervention, Dual Antiplatelet Therapy
- Trial name
- NCT03287167
- Testing
- 1 month DAPT, 6 months DAPT
- Where
- China
- Volunteers
- 1,720 people
- Sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
Coronary Artery Disease Progression
Relation Among HDL Functionality, Neoatherosclerosis and Target Lesion Revascularization
The aim of this study is to evaluate the relation among cholesterol uptake capacity which measure HDL functionality, neoathrosclerosis and target-lesion revascularization.
- Trial name
- NCT03540381
- Testing
- neoatherosclerosis
- Where
- Japan
- Volunteers
- 181 people
- Sponsor
- Kobe University
Coronary Artery Disease
Study Safety and Performance of the Biomime Stent in Patients With Single, De Novo, Non-Complex Coronary Lesions
1.) Indigenously developed and designed BioMimeTM is a predictably safe \& efficacious 3rd generation drug eluting stent (DES) with a propensity to minimize vascular injury by use of an intelligent mix of ultra-low strut…
- Trial name
- meriT-1 (NCT01507519)
- Testing
- Sirolimus Eluting Coronary Stent System (Biomime)
- Where
- India
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Meril Life Sciences Pvt. Ltd.
Coronary Artery Disease
An Evaluation of the Commercially Available Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System
The purpose of this post approval study is to conduct a prospective, multicenter evaluation of the procedural and clinical outcomes of subjects that are treated with the commercially available Medtronic Resolute Integrity…
- Trial name
- RI-US (NCT01638507)
- Testing
- Resolute Integrity Stent
- Where
- United States
- Volunteers
- 230 people
- Sponsor
- Medtronic Vascular
Hypertension, Coronary Arteriosclerosis
Inflammation and Coronary Artery Disease: Role of AT1-Receptor Antagonism
Effects of AT1 receptor antagonist telmisartan on the primary endpoint inflammatory parameters in patients with coronary artery disease (CAD). Secondary endpoints are alterations in clinical course and blood pressure
- Trial name
- NCT00274144
- Testing
- telmisartan 40 mg
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.